Cytosorbents Corporation (NASDAQ:CTSO) has been given a $13.00 target price by research analysts at HC Wainwright in a research report issued on Tuesday. The firm presently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price objective would indicate a potential upside of 179.57% from the stock’s current price.

A number of other analysts have also commented on CTSO. B. Riley reissued a “buy” rating and issued a $11.25 price objective on shares of Cytosorbents Corporation in a research report on Tuesday, April 11th. Maxim Group upped their price target on shares of Cytosorbents Corporation from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday. Cowen and Company began coverage on shares of Cytosorbents Corporation in a research report on Wednesday, June 7th. They set an “outperform” rating and a $7.00 price target on the stock. Finally, Aegis reaffirmed a “buy” rating and set a $9.00 price target on shares of Cytosorbents Corporation in a research report on Tuesday, July 25th. Six investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $12.71.

Shares of Cytosorbents Corporation (NASDAQ:CTSO) opened at 4.65 on Tuesday. The firm has a 50-day moving average of $4.71 and a 200-day moving average of $4.86. The stock’s market cap is $130.70 million. Cytosorbents Corporation has a 52-week low of $3.30 and a 52-week high of $6.90.

Cytosorbents Corporation (NASDAQ:CTSO) last announced its quarterly earnings data on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.02. The business had revenue of $3.57 million for the quarter, compared to analyst estimates of $3.29 million. Cytosorbents Corporation had a negative net margin of 80.56% and a negative return on equity of 529.95%. On average, equities analysts expect that Cytosorbents Corporation will post ($0.27) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/10/cytosorbents-corporation-nasdaqctso-pt-set-at-13-00-by-hc-wainwright.html.

In other Cytosorbents Corporation news, insider Phillip P. Chan purchased 6,300 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $25,200.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders acquired 17,500 shares of company stock worth $70,620. Corporate insiders own 5.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. Segantii Capital Management Ltd increased its position in Cytosorbents Corporation by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock valued at $122,000 after buying an additional 23,100 shares during the period. Cowen Group Inc. acquired a new position in Cytosorbents Corporation during the first quarter valued at approximately $248,000. Sabby Management LLC acquired a new position in Cytosorbents Corporation during the first quarter valued at approximately $990,000. Finally, Skylands Capital LLC increased its position in Cytosorbents Corporation by 87.7% in the second quarter. Skylands Capital LLC now owns 594,250 shares of the medical research company’s stock valued at $2,555,000 after buying an additional 277,650 shares during the period. Institutional investors and hedge funds own 9.74% of the company’s stock.

Cytosorbents Corporation Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Stock Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related stocks with our FREE daily email newsletter.